Fanni Rencz1,2, László Gulácsi3, Michael Drummond4, Dominik Golicki5, Valentina Prevolnik Rupel6, Judit Simon7, Elly A Stolk8, Valentin Brodszky1, Petra Baji1, Jakub Závada9, Guenka Petrova10, Alexandru Rotar11, Márta Péntek1. 1. Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., Budapest, H-1093, Hungary. 2. Semmelweis University Doctoral School of Clinical Medicine, Üllői út 26., Budapest, H-1085, Hungary. 3. Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., Budapest, H-1093, Hungary. laszlo.gulacsi@uni-corvinus.hu. 4. Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK. 5. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland, ul. Banacha 1b, 02-097, Warsaw, Poland. 6. Institute for Economic Research, Kardeljeva ploščad 17, 1000, Ljubljana, Slovenia. 7. Department of Health Economics, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15/1, 1090, Vienna, Austria. 8. Institute of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. 9. Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Na Slupi 4, 128 00, Prague, Czech Republic. 10. Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University, Sofia, Bulgaria. 11. Department of Social Medicine, University of Amsterdam, Meibergdreef 9, 22660, 1100 DD, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries. METHODS: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets. RESULTS: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set. CONCLUSIONS: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.
OBJECTIVE: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries. METHODS: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets. RESULTS: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set. CONCLUSIONS: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.
Entities:
Keywords:
Central and Eastern Europe; Cost-effectiveness analysis; EQ-5D; Health technology assessment; Health-related quality of life; Value sets
Authors: K Érsek; T Kovács; A Wimo; K Kárpati; V Brodszky; M Péntek; L Jönsson; A Gustavsson; D McDaid; P A Kenigsberg; H Valtonen; L Gulácsi Journal: J Nutr Health Aging Date: 2010-10 Impact factor: 4.075
Authors: Marta Dudzińska; Jerzy S Tarach; Agnieszka Zwolak; Maria Kurowska; Joanna Malicka; Agata Smoleń; Andrzej Nowakowski Journal: Ann Agric Environ Med Date: 2013 Impact factor: 1.447
Authors: Delphine De Smedt; Els Clays; Frank Doyle; Kornelia Kotseva; Christof Prugger; Andrzej Pająk; Catriona Jennings; David Wood; Dirk De Bacquer Journal: Int J Cardiol Date: 2012-06-28 Impact factor: 4.164
Authors: Á Kulisch; Á Benkö; A Bergmann; N Gyarmati; Horváth Horváth; Á Kránicz; Z S Mándó; Á Matán; A Németh; E Szakál; D Szántó; L Szekeres; T Bender Journal: Eur J Phys Rehabil Med Date: 2014-03-05 Impact factor: 2.874
Authors: Stefan Höfer; Werner Kullich; Ursula Graninger; Manfred Wonisch; Alfred Gassner; Martin Klicpera; Herbert Laimer; Christiane Marko; Helmut Schwann; Rudolf Müller Journal: Health Qual Life Outcomes Date: 2009-12-08 Impact factor: 3.186
Authors: Fanni Rencz; Peter L Lakatos; László Gulácsi; Valentin Brodszky; Zsuzsanna Kürti; Szilvia Lovas; János Banai; László Herszényi; Tamás Cserni; Tamás Molnár; Márta Péntek; Károly Palatka Journal: Qual Life Res Date: 2018-09-17 Impact factor: 4.147
Authors: Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek Journal: Qual Life Res Date: 2017-09-05 Impact factor: 4.147